(1-3)-β-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections

Clinical Infectious Diseases

Volumn 56, Issue 10, 2013, Pages 1511-1512

  Mikulska, Małgorzata ^a   Furfaro, Elisa ^a   Del Bono, Valerio ^a   Raiola, Anna Maria ^a   Di Grazia, Carmen ^a   Bacigalupo, Andrea ^a   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(1 3) BETA DEXTRO GLUCAN; BIOLOGICAL MARKER; GALACTOMANNAN; UNCLASSIFIED DRUG;

APHASIA; ASPERGILLUS; CANDIDA; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; COMA; CONFUSION; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; FEVER; HEMIPARESIS; HIGH RISK PATIENT; HISTOPLASMOSIS; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; LETTER; LUMBAR PUNCTURE; LUNG ASPERGILLOSIS; MENINGOENCEPHALITIS; MUCORALES; NEUROLOGIC DISEASE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; SYSTEMIC MYCOSIS;

ADULT; BETA-GLUCANS; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84877294244     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit073     Document Type: Letter

References (10)

1. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
2. Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002; 40:1496-9.
3. Petraitiene R, Petraitis V, Hope WW, et al. Cerebrospinal fluid and plasma (1-3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis. Antimicrob Agents Chemother 2008; 52:4121-9.
4. Miyazaki T, Kohno S, Mitsutake K, et al. Plasma (1-3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis and cryptococcosis. J Clin Microbiol 1995; 33:3115-8.
5. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, McGinnis MR, Ostrosky-Zeichner L. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol 2006; 44:267-72.
6. Mitsutake K, Miyazaki T, Tashiro T, et al. Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia. J Clin Microbiol 1996; 34:1918-21.
7. Akamatsu N, Sugawara Y, Kaneko J, Tamura S, Makuuchi M. Preemptive treatment of fungal infection based on plasma (1-3)-beta-D-glucan levels after liver transplantation. Infect 2007; 35:346-51.
8. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1-3)-beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654-9.
9. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1-3)-beta-D-glucan assay for the diagnosis of invasive fungal infections-a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46:1864-70.
10. Bellanger AP, Grenouillet F, Henon T, et al. Retrospective assessment of β-D-(1,3)-glucan for presumptive diagnosis of fungal infections. APMIS 2011; 119:280-6.